Powering up medical affairs
Technology is enabling more resources to reach the medical affairs teams—in a compliant manner
Enough already with REMS abuse in generic drug development
3PLs set specialty pharmaceutical markets in motion
Managing the physical movement of specialty drugs calls for dedicated services
In the track-and-trace trenches
As the pharma industry moves ahead with traceability initiatives, vendors are building their capabilities
Consider enterprise quality management systems for GDP tasks
The growing compliance requirements for distribution call for a streamlined approach
Changing of the guard at PDMA Alliance
When it Comes to Compliance, Learning Never Stops
Cardiovascular therapy: More new drugs for a growing patient base
The scale of the cardiovascular market pushes payers to demand quality outcomes data
Battle fronts in the illicit online pharmacy war
The annual Operation Pangea nets a next crop of crooks; consumer groups raise awareness
A conversation with Terry Hisey, Deloitte
The keys to a successful and impactful partnership: A case study
Dealing with biologics production uncertainty
The biologics development and approval process for pharmaceutical companies around the world is typically long and complex, which increases the risk of inaccurately forecasting demand
Projected 2017 medical cost growth will be 'flat,' says PwC
A repeat of the +6.5% cost trend indicates that medical costs are still rising above inflation
A whiff of scandal in Mexican drug distribution
Panama Papers point to secret merger between distributors
IMS Health and Reltio tighten their collaboration
Reltio Cloud master-data management will glue together IMS data resources
Catalent continues expanding clinical supply resources in Asia
New Kakegawa, Japan, facility will handle storage and packaging
HDMA is now the Healthcare Distribution Alliance
Internationalization of drug wholesaling is a factor in the name change
FDA streamlines its ‘compassionate use’ process
New physician’s form is supposed to reduce the complexity of obtaining investigational drugs
Global oncology drug market was $107 billion in 2015, up 11.5%
Branded products are 92% US market in dollar value, says IMS Institute
Regeneron takes over as sponsor of the Science Talent Search
Prestigious competition for budding scientists takes a biotech vibe
UPS Foundation funds medical deliveries by drone in Africa
Pilot program in Rwanda has commercial potential
Veeva expands its cloud-based offerings into product master data
Looming EU IDMP mandates are only part of the potential applications
